ProSomnus, Inc. (OSAPQ)
| Market Cap | 469.13K |
| Revenue (ttm) | 27.65M |
| Net Income (ttm) | -24.10M |
| Shares Out | 16.18M |
| EPS (ttm) | -1.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,646 |
| Open | 0.0164 |
| Previous Close | 0.0156 |
| Day's Range | 0.0150 - 0.0350 |
| 52-Week Range | 0.0080 - 0.3000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About OSAPQ
ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California. On May 7, 2024, ProSomnus, Inc., along with its affiliates, filed a voluntary petition for reorganiz... [Read more]
Financial Performance
In 2023, ProSomnus's revenue was $27.65 million, an increase of 42.59% compared to the previous year's $19.39 million. Losses were -$24.10 million, 237.2% more than in 2022.
Financial numbers in USD Financial StatementsNews
Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices
PLEASANTON, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that four independent scientific abstracts ...